Seqens Seqens

X
[{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder Based On Patient Feedback","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Jeeva clinical Trials","sponsor":"Redwood Scientific Technologies Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Redwood Scientific Enters into Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips for Smoking and E-cigarette Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Jeeva clinical Trials"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Jeeva clinical Trials

            Contact Supplier
            • Deals
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            The agreement aims to launch a clinical effectiveness study of its TBX-Free oral strips (cytisine) products, acts similarly to nicotine where it can stimulate receptors in the brain, for smoking and e-cigarette cessation.

            Lead Product(s): Cytisine

            Therapeutic Area: Psychiatry/Psychology Product Name: TBX-FREE

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Redwood Scientific Technologies Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 06, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            One of co-primary endpoints of study on adjunctive Rexulti (brexpiprazole) in adults with MDD and inadequate response to ADT was new exploratory outcome focusing on positive health aspects across emotional, physical, social, and cognitive domains.

            Lead Product(s): Brexpiprazole

            Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: H. Lundbeck AS

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY